Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Regeneron Pharmaceuticals is conducting a study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study aims to estimate the incidence of retinal vasculitis (RV) among adult patients receiving aflibercept 2 mg in the United States. This research is significant as it seeks to provide real-world insights into the safety profile of aflibercept, a drug widely used in ophthalmology.
Intervention/Treatment: The study focuses on the drug aflibercept 2 mg, administered intravitreally (IVT) as Eylea®. The purpose of this treatment is to manage retinal conditions, and the study will assess its association with RV events.
Study Design: This is an observational, retrospective cohort study. It utilizes secondary data from the IRIS Registry to identify and confirm cases of RV among patients treated with aflibercept. The study does not involve any new interventions or experimental procedures.
Study Timeline: The study began on July 1, 2025, with its primary completion and estimated completion dates yet to be determined. The last update was submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
Market Implications: This study could influence Regeneron’s stock performance and investor sentiment by providing critical data on the safety of aflibercept. Positive findings may strengthen Regeneron’s market position, while any safety concerns could impact its competitive standing in the ophthalmology sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.